Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan.

ABSTRACT:

Background

The effectiveness of fremanezumab in treating migraine has been demonstrated in randomized controlled trials. However, real-world study results are still limited.

Methods

We conducted a single-center, observational study that included patients with episodic migraine (EM) and chronic migraine (CM) who received fremanezumab monthly or quarterly over 6-month periods. The primary outcome of this study was to evaluate changes in monthly migraine days (MMD) and responder achievement after treatment with fremanezumab. The secondary aim was to characterize the predictors of responder at 6 months. We also evaluated the effectiveness of fremanezumab in the patients who switched from other calcitonin gene-related peptide (CGRP) monoclonal antibodies, and compared the effecti

SUBMITTER: Suzuki S 

PROVIDER: S-EPMC10359132 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature